FOXM1 and colorectal carcinoma: Other studies describe a high expression of FOXM1 in samples from mCRC patients in poorly differentiated and proliferative tumors, but with a high rate of response to treatment and propose FOXM1 as a predictive marker of response to therapy in a subset of CRC patients [25, 26].